Which rare coagulopathy is associated with very large hepatic hemangiomas?

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

Multiple Choice

Which rare coagulopathy is associated with very large hepatic hemangiomas?

Kasabach-Merritt phenomenon is a consumptive coagulopathy that occurs with large vascular tumors, including very large hepatic hemangiomas. In this scenario the tumor acts as a sink for platelets and coagulation factors: platelets are trapped and activated within the abnormal tumor vessels, which starts a local and then systemic activation of coagulation that depletes platelets and fibrinogen and prolongs clotting times. The result is thrombocytopenia, reduced fibrinogen, elevated D-dimers, and a bleeding tendency, despite the absence of classic liver failure. Clinically, you’d expect a rapidly enlarging hepatic lesion with easy bruising or oozing, and lab tests showing low platelets, low fibrinogen, and prolonged PT/PTT with signs of ongoing consumption. Management focuses on stopping the consumption by treating the underlying tumor when possible (such as embolization or resection in suitable cases, with medical therapies like sirolimus or vincristine in others) and correcting the coagulopathy with supportive care. The other options describe systemic or inherited bleeding disorders not specifically tied to a giant hepatic hemangioma, so they don’t explain this tumor-associated coagulopathy.

Kasabach-Merritt phenomenon is a consumptive coagulopathy that occurs with large vascular tumors, including very large hepatic hemangiomas. In this scenario the tumor acts as a sink for platelets and coagulation factors: platelets are trapped and activated within the abnormal tumor vessels, which starts a local and then systemic activation of coagulation that depletes platelets and fibrinogen and prolongs clotting times. The result is thrombocytopenia, reduced fibrinogen, elevated D-dimers, and a bleeding tendency, despite the absence of classic liver failure. Clinically, you’d expect a rapidly enlarging hepatic lesion with easy bruising or oozing, and lab tests showing low platelets, low fibrinogen, and prolonged PT/PTT with signs of ongoing consumption. Management focuses on stopping the consumption by treating the underlying tumor when possible (such as embolization or resection in suitable cases, with medical therapies like sirolimus or vincristine in others) and correcting the coagulopathy with supportive care. The other options describe systemic or inherited bleeding disorders not specifically tied to a giant hepatic hemangioma, so they don’t explain this tumor-associated coagulopathy.

More practice questions